|
|
|
|
Office Locations:
|
100 East Pratt Street
Baltimore, MD 21202
Phone: 410-345-2000
| | |
|
|
|
|
|
Information Technology
Media & Digital Media
Software & Internet
|
|
|
|
T. Rowe Price (TROW) is an independent investment management firm with an unyielding focus on helping investors around the world achieve their long-term goals. Headquartered in Baltimore, the firm provides a broad array of mutual funds, subadvisory services, separate account management, and related services for individuals, institutions, retirement plan sponsors, and financial intermediaries. T. Rowe Price selectively makes investments in later stage venture capital opportunities.
|
|
|
|
|
Investment Firm Key
VC = Venture Capital
PE = Private Equity
A = Angel
I = Incubator
MB = Merchant Bank
VD = Venture Debt
FI = Family Investment Office
FOF = Fund of Funds
ED = Economic Development Office
TT = Technology Transfer Office
CVC = Corporate Venture Capital
SEC = Secondary Purchaser
HF = Hedge Fund/Mutual Fund
|
|
| COMPANY STAGE | REVENUE |
| Venture Capital | |
Seed Stage
(includes "pre-seed," or
concept stage) | No Revenue |
| Early Stage | Minimal
Revenue |
Growth Stage
(also called Mid-stage) | $2M-$7M |
Expansion Stage
(also called Late-stage) | $7M and greater |
| Private Equity | |
| Lower Middle Market | $10M-$249M |
| Middle Market | $250M-$499M |
| Upper Middle Market | $500M-$1B |
| Large Cap | >$1B |
|
|
|
|
|
|
|
| Name | |
| |
Title | |
Get the complete investment team + individual email addresses for investment team partners. Get personal images, LinkedIn links, investment specialties, office locations and more with a National Database subscription.
|
| Celine Dufétel | |
| |
COO and CFO | |
| Dee Sawyer | |
| |
Head of Individual Investors and Retirement Plan Services | |
| Nigel Faulkner | |
| |
Head of Global Technology | |
| William Stromberg | |
| |
CEO | |
|
|
|
|
Date
|
Name
|
State
|
Amount
|
Stage
|
12/18/2024
|
SandboxAQ
|
CA
|
$300,000,000
|
|
11/07/2024
|
Seaport Therapeutics
|
MA
|
$225,000,000
|
Series B
|
10/17/2024
|
Aktis Oncology
|
MA
|
$175,000,000
|
Series B
|
10/16/2024
|
Lightmatter
|
CA
|
$400,000,000
|
Series D
|
09/04/2024
|
ArsenalBio
|
CA
|
$325,000,000
|
Series C
|
08/05/2024
|
MBX Biosciences
|
IN
|
$63,500,000
|
Series C
|
07/24/2024
|
Kestra
|
WA
|
$196,000,000
|
|
07/23/2024
|
Third Arc Bio
|
MA
|
$165,000,000
|
Series A
|
07/23/2024
|
Clio
|
NY
|
$900,000,000
|
Series F
|
07/11/2024
|
Element Biosciences
|
CA
|
$277,000,000
|
Series D
|
06/27/2024
|
Sila Nanotechnologies
|
CA
|
$375,000,000
|
Series G
|
04/25/2024
|
Endeavor BioMedicines
|
CA
|
$132,500,000
|
Series C
|
02/15/2024
|
Lambda
|
CA
|
$320,000,000
|
Series C
|
02/13/2024
|
ProfoundBio
|
WA
|
$112,000,000
|
Series B
|
|
|
|
|
|
|
|
